HS
VRCA icon

HighVista Strategies’s Verrica Pharmaceuticals VRCA Stock Holding History

HighVista Strategies’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,094
Closed -$137K – 119
2021
Q3 		$137K Buy
+1,094
New +$123K 0.09% 78

Other funds holding VRCA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

HighVista Strategies's VRCA Position: Q4 2021 in Review

HighVista Strategies sold out of Verrica Pharmaceuticals (VRCA) in Q4 2021, closing a stake of 1,094 shares — an estimated $137K sold.

HighVista Strategies first reported a position in VRCA in Q3 2021 and held it in 1 quarter. The position peaked at $137K in Q3 2021. 45 funds tracked by Wall St. Rank hold VRCA as of Q4 2021.

  • HighVista Strategies reported no remaining Verrica Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • HighVista Strategies sold 1,094 Verrica Pharmaceuticals shares in Q4 2021, an estimated $137K.
  • HighVista Strategies first reported a position in Verrica Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • HighVista Strategies's Verrica Pharmaceuticals position peaked at $137K in Q3 2021.
  • 45 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q4 2021.

Based on HighVista Strategies's 13F filing for Q4 2021, filed 14 Feb 2022.